亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50%

医学 免疫疗法 肿瘤科 内科学 癌症
作者
Xiangyu Li,Wei Wang,Chunhua Xu,Yuan Qi
出处
期刊:Current Cancer Drug Targets [Bentham Science Publishers]
卷期号:25 (7): 818-828 被引量:1
标识
DOI:10.2174/0115680096364469250113105648
摘要

Background: Non-small cell lung cancer (NSCLC) predominantly affects older adults; these patients have significant comorbidities, making them unsuitable for chemo-therapy. This study aimed to evaluate the efficacy and safety of immune checkpoint in-hibitor (ICI) along with anlotinib combination therapy as a first-line treatment in older NSCLC patients with programmed death ligand-1(PD-L1) expression<50%. Methods: We conducted a retrospective observational study including 73 patients with ad-vanced NSCLC treated at Nanjing Brain Hospital. All patients were aged 75 years or older and received first-line systemic therapy with a combination of PD-1 inhibitors and anlo-tinib. Clinical data were obtained from electronic medical records and analyzed through Kaplan-Meier estimates and Cox proportional hazards models to assess progression-free survival (PFS), overall survival (OS), and the influence of different variables. Results: The patients had a median age of 80 years. The median PFS was 9.8 months (95% CI: 7.9-11.7), and the median OS was 19.5 months (95% CI: 17.3-21.7). PD-L1 tu-mor proportion score (TPS) <1% (χ2=10.263, P=0.001) and absence of treatment-induced hypertension (χ2=12.804, P<0.001) were identified as independent risk factors for poor PFS. Advanced disease stage (χ2=11.900, P=0.001), PD-L1 TPS <1% (χ2=6.643, P=0.010), and having two or more chronic comorbidities (χ2=9.011, P=0.003) were inde-pendent risk factors for poor OS. Treatment-related hypertension was observed in 25% of patients and was associated with better PFS. Conclusion: ICI-anlotinib combination therapy showed promising efficacy and an ac-ceptable safety profile in older NSCLC patients. Future studies involving larger popula-tions are necessary to validate these findings and determine the potential of PD-L1 levels as a biomarker for treatment stratification.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
amiee发布了新的文献求助10
10秒前
李爱国的应助被wubin69采纳,获得10
13秒前
愤怒的若颜完成签到,获得积分10
14秒前
Youy完成签到 ,获得积分10
17秒前
23秒前
wubin69发布了新的文献求助10
31秒前
魔幻萃完成签到,获得积分10
31秒前
典雅的醉易完成签到,获得积分10
44秒前
50秒前
50秒前
50秒前
null的应助被科研通管家采纳,获得10
50秒前
52秒前
科研通AI6.3的应助被wubin69采纳,获得10
58秒前
独特珩完成签到,获得积分10
1分钟前
xiaoshulin完成签到,获得积分10
1分钟前
传奇3的应助被炙热白开水采纳,获得20
1分钟前
NeoAir完成签到 ,获得积分10
1分钟前
曹博完成签到 ,获得积分10
1分钟前
幸福的盼芙完成签到,获得积分10
1分钟前
动听的山槐完成签到,获得积分10
1分钟前
2分钟前
独特的雅霜完成签到,获得积分10
2分钟前
2分钟前
York Chang发布了新的文献求助10
2分钟前
2589发布了新的文献求助10
2分钟前
失眠雪柳完成签到,获得积分10
2分钟前
2分钟前
从容美女发布了新的文献求助10
2分钟前
York Chang完成签到,获得积分20
2分钟前
直率的晓亦完成签到,获得积分10
2分钟前
3分钟前
白奕发布了新的文献求助10
3分钟前
怕孤独的白猫完成签到,获得积分10
3分钟前
科研通AI6.3的应助被ny960采纳,获得10
3分钟前
要减肥青曼完成签到,获得积分10
3分钟前
4分钟前
小屋完成签到,获得积分10
4分钟前
ny960发布了新的文献求助10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185215
求助须知:如何正确求助?哪些是违规求助? 9574085
关于积分的说明 21834197
捐赠科研通 7782763
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558801
邀请新用户注册赠送积分活动 2481237